Advertisement

Journal of Neuro-Oncology

, Volume 109, Issue 3, pp 545–553 | Cite as

Nuclear karyopherin a2: a novel biomarker for infiltrative astrocytomas

  • K. GousiasEmail author
  • A. J. Becker
  • M. Simon
  • P. Niehusmann
Clinical Study

Abstract

The karyopherin (KPNA) protein family is involved in nucleocytoplasmic trafficking. Increased KPNA levels have been found to predict poor prognosis for a variety of solid tumors, including breast, ovarian, cervical, and prostate cancer, and melanoma. The purpose of this study was to evaluate karyopherin a2 as novel biomarker for astrocytic gliomas of WHO grades II–IV. We semiquantitatively measured nuclear expression of karyopherin a2 and the MIB1 labeling index, by immunohistochemical analysis, for 94 primary (23 astrocytomas WHO grade II, 24 astrocytomas WHO grade III, 47 glioblastomas) and 12 recurrent gliomas. In addition, IDH1 mutation status and Nijmegen breakage syndrome 1 protein expression were assessed, by immunohistochemical analysis, for all 71 malignant (WHO grade III and IV) and all 94 primary gliomas, respectively. Statistical analysis was performed by use of standard techniques. Karyopherin a2 expression correlated significantly with histological grade (p < 0.001), with proliferative activity as assessed by the MIB1 index (p < 0.001), with IDH1 mutation status (p = 0.032), and with Nijmegen breakage syndrome 1 protein expression (p = 0.001). Recurrent tumors expressed significantly higher levels of karyopherin a2 (p = 0.045) than primary growths. Multivariate analysis of the overall series identified low karyopherin a2 expression (defined as less than 5 %) as an independent prognostic predictor of overall (p = 0.041) and progression-free survival (p = 0.004). Survival of glioblastoma patients >5 years was seen only in those with KPNA2 expression levels ≤1 % (p = 0.014). KPNA2 expression may have potential as a novel diagnostic and prognostic biomarker for astrocytic gliomas.

Keywords

Karyopherin a2 Infiltrative astrocytomas NBS1 protein IDH1 mutation Prognosis Biomarker 

Notes

Acknowledgments

The results in this paper form the doctoral thesis (University of Bonn) of KG.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Central brain tumor registry of the United States. http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf. Accessed 20 January 2012
  2. 2.
    Stummer W, Reulen HJ, Meinel T, Pichlmeier W, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T ALA-Glioma Study Group (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62(3):564–576Google Scholar
  3. 3.
    Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, VandenBerg S, McDermott MW, Berger MS (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. JCO 26:1338–1345CrossRefGoogle Scholar
  4. 4.
    Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479PubMedCrossRefGoogle Scholar
  5. 5.
    Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, Goldbrunner R, Krex D, Steinbach JP, Ostertag CB, Loeffler M, Pietsch T, von Deimling A, German Glioma Network (2007) Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13(23):6933–6937PubMedCrossRefGoogle Scholar
  6. 6.
    Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003PubMedCrossRefGoogle Scholar
  7. 7.
    Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, Wick W, Kortmann RD, Reifenberger G, Weller M, Herrlinger U (2009) Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 27(8):1257–1261PubMedCrossRefGoogle Scholar
  8. 8.
    Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120(6):707–718PubMedCrossRefGoogle Scholar
  9. 9.
    Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, Stein R, Reifenberger G, Pietsch T, von Deimling A, Loeffler M, Weller M, German Glioma Network (2011) Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 17(13):4588–4599PubMedCrossRefGoogle Scholar
  10. 10.
    Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K, Wang XW, Loundou A, Chapon F, Pineau S, Ouafik L, Chinot O, Figarella-Branger D (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120(6):719–729PubMedCrossRefGoogle Scholar
  11. 11.
    Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A, Kreth FW (2012) IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer 118(2):452–460PubMedCrossRefGoogle Scholar
  12. 12.
    Yan H, Parsons DW, Jin G, McLendon R, Rasheed A, Yuan W, Kos I, Batinic-Haberle I, Jones I, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler WK, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773PubMedCrossRefGoogle Scholar
  13. 13.
    Zannini L, Lecis D, Lisanti S, Benetti R, Buscemi G, Schneider C, Delia D (2003) Karyophrin-a2 protein interacts with Chk2 and contributes to its nuclear import. J Biol Chem 278:42346–42351PubMedCrossRefGoogle Scholar
  14. 14.
    Tseng SF, Chang CY, Wu KJ, Teng SC (2005) Importin KPNA2 is required for proper nuclear localization and multiple functions of NSB1. J Biol Chem 280:39594–39600PubMedCrossRefGoogle Scholar
  15. 15.
    Chen YC, Su YN, Chou PC, Chiang WC, Chang MC, Wang LS, Teng SC, Wu KJ (2005) Overexpression of NBS1 contributes to transformation through the activation of phosphatidylinositol 3-kinase/Akt. J Biol Chem 280(37):32505–32511PubMedCrossRefGoogle Scholar
  16. 16.
    Teng SC, Wu KJ, Tseng SF, Wong CW, Kao L (2006) Importin KPNA2, NSB1, DNA repair and tumorigenesis. J Mol Histol 37:293–299PubMedCrossRefGoogle Scholar
  17. 17.
    Antoccia A, Kobayashi J, Tauchi H, Matsuura S, Komatsu K (2006) Nijmegen breakage syndrome and functions of the responsible protein, NSB1. Genome Dyn 1:191–205PubMedCrossRefGoogle Scholar
  18. 18.
    Kim IS, Kim DH, Han SM, Chin MU, Nam HJ, Cho HP, Choi SY, Song BJ, Kim ER, Bae YS, Moon YH (2000) Truncated form of importin a identified in breast cancer cell inhibits nuclear import of p53. J Biol Chem 275:23139–23145PubMedCrossRefGoogle Scholar
  19. 19.
    Moll UM, LaQuaqlia M, Benard J, Riou G (1995) Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92:4407–4411PubMedCrossRefGoogle Scholar
  20. 20.
    Noetzel E, Rose M, Bornemann J, Gajewski M, Knüchel R, Dahl E (2011) Nuclear transport receptor karyopherin-a2 promotes malignant breast cancer phenotypes in vitro. Oncogene doi. doi: 10.1038/onc.2011.403
  21. 21.
  22. 22.
  23. 23.
    Zheng M, Tang L, Huang L, Ding H, Liao WT, Zeng MS, Wang H (2010) Overexpression of karyopherin-2 in epithelial ovarian cancer and correlation with poor prognosis. Obstet Gynecol 116(4):884–891PubMedCrossRefGoogle Scholar
  24. 24.
    Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, Hermann K, Pilarsky C, Dürst M, Klinkhammer-Schalke M, Blaszyk H, Knuechel R, Hartmann A, Rosenthal A, Wild PJ (2006) Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin a2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res 12(13):3950–3960PubMedCrossRefGoogle Scholar
  25. 25.
    van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, Birrer MJ, Leaner VD (2009) The karyopherin proteins, Crm1 and Karyopherin b1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 124:1829–1840PubMedCrossRefGoogle Scholar
  26. 26.
    Mortezavi A, Hermanns T, Seifert HH, Baumgartner MK, Provenzano M, Sulser T, Burger M, Montani M, Ikenberg K, Hofstädter F, Hartmann A, Jaggi R, Moch H, Kristiansen G, Wild PJ (2011) KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 17(5):1111–1121PubMedCrossRefGoogle Scholar
  27. 27.
    Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A, Melanoma Group of the European Organization for Research and Treatment of Cancer (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98(7):472–482PubMedCrossRefGoogle Scholar
  28. 28.
    Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20(1):245–254PubMedCrossRefGoogle Scholar
  29. 29.
    Dankof A, Fritzsche FR, Dahl E, Pahl S, Wild P, Dietel M, Hartmann A, Kristiansen G (2007) KPNA2 protein expression in invasive breast carcinoma and matched peritumoral ductal carcinoma in situ. Virchows Arch 451:877–881PubMedCrossRefGoogle Scholar
  30. 30.
    Gluz O, Wild P, Meiler R, Diallo-Danebrock R, Ting E, Mohrmann S, Schuett G, Dahl E, Fuchs T, Herr A, Gaumann A, Frick M, Poremba C, Nilz UA, Hartmann A (2008) Nuclear karyopherin a2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity. Int J Cancer 123:1433–1438PubMedCrossRefGoogle Scholar
  31. 31.
    Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histological grade to improve prognosis. J Natl Cancer Inst 98:262–272PubMedCrossRefGoogle Scholar
  32. 32.
    Wang CI, Wang CL, Wang CW, Chen CD, Wu CC, Liang Y, Tsai YH, Chang YS, Yu JS, Yu CJ (2010) Importin subunit alpha-2 is identified as a potential biomarker for non-small cell lung cancer by integration of the cancer cell secretome and tissue transcriptome. Int J Cancer 128(10):2364–2372CrossRefGoogle Scholar
  33. 33.
    Mirzoeva OK, Kawaguchi T, Pieper RO (2006) The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity. Mol Cancer Ther 5(11):2757–2766PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • K. Gousias
    • 1
    Email author
  • A. J. Becker
    • 2
  • M. Simon
    • 1
  • P. Niehusmann
    • 2
  1. 1.Department of NeurosurgeryUniversity Hospital of BonnBonnGermany
  2. 2.Department of NeuropathologyUniversity Hospital of BonnBonnGermany

Personalised recommendations